Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsVentura County Zavesca Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentVentura County Health Care PlanPolicy N/A

    Zavesca (miglustat capsules) Formulary Exception Policy

    Customize your policy alerts

    Sign up for all venturacountyhealthcareplan policy alerts

    Know when venturacountyhealthcareplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs formulary-exception requests for brand Zavesca (miglustat capsules) for members with Gaucher disease Type I. It defines the specialist, prior treatment, formulation-related adverse-reaction, and documentation requirements for approval.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyZavesca (miglustat capsules) Formulary Exception Policy
    Policy CodePolicy N/A
    Change TypeAnnual revisionno criteria changes
    Effective DateAug 5, 2020
    Next Review DateN/A
    Key ActionBefore brand Zavesca can be approved, document trials of both Cerdelga and generic miglustat.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 yearApproval duration when criteria are met
    3Required coverage criteria
    2Required prior products tried
    Gaucher disease Type ICovered indication

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Gaucher Disease Type I Coverage Criteria

    Gaucher Disease Type I

    Approve for 1 year when all of the following criteria are met:

    All required criteria

    • Criterion A — Specialist involvement: Zavesca is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician who specializes in the treatment of Gaucher disease or related disorders.
    • Criterion B — Required prior trials: The patient has tried BOTH Cerdelga (eliglustat capsules) and generic miglustat.

      Documentation is required for both products.

    • Criterion C — Formulation-related adverse reaction: Brand Zavesca is being requested due to a formulation difference in the inactive ingredient(s), such as preservatives, between the brand and the bioequivalent generic miglustat product that, per the prescribing physician, has or would result in a significant allergy or serious adverse reaction.

    Initial Therapy for Brand Zavesca

    Initial approval for Gaucher disease Type I

    Approve brand Zavesca for 1 year when all of the following criteria are met:

    All initial approval criteria

    • Specialist involvement: Zavesca is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder sub-specialist, or a physician specializing in Gaucher disease or related disorders.
    • Prior treatment: The patient has tried BOTH Cerdelga (eliglustat capsules) and generic miglustat.

      Documentation is required for both products.

    • Brand-specific formulation need: The prescribing physician states that a formulation difference in the inactive ingredient(s), such as preservatives, between brand Zavesca and the bioequivalent generic miglustat product has or would result in a significant allergy or serious adverse reaction.Significant allergy or serious adverse reaction

    Preferred Alternatives

    StepRequired prior therapyRequirement
    1Cerdelga (eliglustat capsules) and generic miglustatThe patient must have tried both products before requesting brand Zavesca.

    Requirements for Submission and Approval

    Prior Authorization

    Meet All Zavesca Exception Criteria

    For 1-year approval of brand Zavesca for Gaucher disease type I, the prescription must be written by or made in consultation with a geneticist, endocrinologist, metabolic-disorder subspecialist, or physician specializing in Gaucher disease or related disorders. The patient must have tried both preferred alternatives and the request must be due to an inactive-ingredient formulation difference that has caused, or is expected to cause, a significant allergy or serious adverse reaction to bioequivalent generic miglustat, as documented by the prescribing physician.

    • Indication: Gaucher disease type I.
    • Specialist involvement is required.
    • The request must address a formulation difference in inactive ingredients (for example, preservatives) between brand Zavesca and bioequivalent generic miglustat.
    • The prescribing physician must document that the formulation difference has caused or would result in a significant allergy or serious adverse reaction.
    Step Therapy

    Try Both Preferred Alternatives

    Before brand Zavesca can be approved, document trials of both preferred alternatives: Cerdelga (eliglustat capsules) and generic miglustat. Both product trials are required.

    • Trial of Cerdelga (eliglustat capsules) is required.
    • Trial of generic miglustat is required.
    • Document the relevant treatment history for each trial.
    Documentation Required

    Submit Treatment History and Clinical Documentation

    Submit treatment-history and clinical documentation supporting the brand Zavesca request. Documentation may include chart notes, prescription claims records, prescription receipts, and/or laboratory data, including evidence of both preferred-product trials and the clinically significant formulation-related allergy or serious adverse reaction.

    • Document the Gaucher disease type I diagnosis and relevant clinical information.
    • Document prescribing by or consultation with the required specialist.
    • Provide records of trials of both Cerdelga (eliglustat capsules) and generic miglustat.
    • Document the inactive-ingredient formulation difference and the prescribing physician's determination that it has caused or would cause a significant allergy or serious adverse reaction.
    • Acceptable supporting records may include chart notes, prescription claims records, prescription receipts, and/or laboratory data.
    Denial Risk

    Failure to Meet All Exception Criteria

    Brand Zavesca will not meet the formulary exception requirements if the patient does not have Gaucher disease type I, the required specialist involvement is absent, either preferred-product trial is not documented, or the formulation-related allergy or serious adverse-reaction criterion and supporting documentation are not met.

    • Requests that fail any required criterion may be denied.
    • Both Cerdelga and generic miglustat trials must be documented.
    • The formulation-related adverse-reaction rationale must be supported by the prescribing physician and relevant clinical records.

    Policy Background

    This policy addresses requests for brand Zavesca (miglustat capsules) for members with Gaucher disease Type I when the requested brand formulation differs from bioequivalent generic miglustat because of inactive ingredients, such as preservatives. Coverage is limited to cases in which the prescribing physician indicates that the formulation difference has caused or would cause a significant allergy or serious adverse reaction.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyZavesca (miglustat capsules) Formulary Exception Policy
    Policy CodePolicy N/A
    Change TypeAnnual revisionno criteria changes
    Effective DateAug 5, 2020
    Next Review DateN/A
    Key ActionBefore brand Zavesca can be approved, document trials of both Cerdelga and generic miglustat.
    SourceLink
    On This Page
    Gaucher Disease Type I Coverage CriteriaInitial Therapy for Brand ZavescaPreferred AlternativesRequirements for Submission and ApprovalPolicy Background